韩国系统性红斑狼疮患者接种两剂佐剂带状疱疹亚单位疫苗的免疫原性、反应原性和安全性:单中心、随机、双盲、安慰剂对照试验
在韩国首尔大学医院风湿科门诊开展的单中心随机双盲安慰剂对照试验中,65例临床稳定的系统性红斑狼疮患者按4:1随机分配至带状疱疹亚单位疫苗组(52例)或安慰剂组(13例),改良意向治疗人群分别为49例和11例。第二剂后4周,疫苗组48例(98%)产生体液免疫应答,安慰剂组0例(0%),差异显著(p<0·0001);疫苗组注射部位反应、发热和疲劳报告例数多于安慰剂组,两组SLEDAI-2K和BILAG flare率无差异,无治疗相关死亡。
要点
- 第二剂后4周,疫苗组48/49例(98%)产生体液免疫应答,安慰剂组0/11例(0%),p<0·0001。
- 疫苗组注射部位反应42例、发热10例、疲劳26例,均多于安慰剂组(分别为2例、0例、2例)。
- 两组SLEDAI-2K和BILAG flare率无差异,无治疗相关死亡。
核心结论
- 带状疱疹亚单位疫苗在系统性红斑狼疮患者中诱导针对带状疱疹的体液免疫和细胞免疫,安全性良好。
- 作者认为需要更大规模的研究来评估疫苗预防系统性红斑狼疮患者带状疱疹的效力。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照试验,在韩国首尔大学医院风湿科门诊开展。
- 纳入年龄≥19岁、临床稳定且既往免疫抑制剂暴露≥4周的系统性红斑狼疮患者,通过中央交互式网络应答系统按4:1随机分配至带状疱疹亚单位疫苗组或安慰剂组,于第0周和第8周肌肉注射0·5 mL。
- 主要结局为第二剂后4周产生阳性体液疫苗应答的患者比例,主要分析和安全性分析在改良意向治疗人群中进行。
- 2023年6月14日至7月19日共纳入65例患者,疫苗组52例、安慰剂组13例,改良意向治疗人群分别为49例和11例;60例中女56例(93%)、男4例(7%),平均年龄48·7岁(SD 11·4)。
主要发现
- 第二剂后4周,疫苗组48/49例(98%)产生体液疫苗应答,安慰剂组0/11例(0%),疫苗组显著高于安慰剂组(p<0·0001)。
- 疫苗组报告注射部位反应42例 vs 安慰剂组2例,发热10例 vs 0例,疲劳26例 vs 2例。
- 两组SLEDAI-2K和BILAG flare率无差异,无治疗相关死亡。
关键数值与推荐
- 体液疫苗应答定义为第二剂后4周产生阳性体液疫苗应答,疫苗组48/49例(98%)vs 安慰剂组0/11例(0%),p<0·0001。
- 抗糖蛋白E抗体滴度和糖蛋白E特异性细胞介导疫苗应答分别在基线和第一剂后第8周、第二剂后第4周、第26周和第52周采用酶联免疫吸附试验和流式细胞术评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要更大规模的研究来评估疫苗预防系统性红斑狼疮患者带状疱疹的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The adjuvanted herpes zoster subunit vaccine has shown good efficacy and safety in the general population. However, its effectiveness has not been comprehensively assessed in patients with systemic lupus erythematosus (SLE). This study aimed to evaluate the immunogenicity and safety of the adjuvanted herpes zoster subunit vaccine in patients with SLE. METHODS: This single-centre, randomised, double-blind, placebo-controlled, trial was done at the rheumatology outpatient clinic at Seoul National University Hospital, South Korea. Patients (aged ≥19 years) with clinically stable SLE and previous exposure (≥4 weeks) to immunosuppressive drugs were randomly assigned (4:1) via a central interactive web response system to receive herpes zoster subunit vaccine or placebo (0·5 mL intramuscular injection) at weeks 0 and 8. Investigators and participants were masked to intervention and group assignment. Anti-glycoprotein E antibody titres and glycoprotein E-specific cell-mediated vaccine responses were evaluated at baseline and at week 8 after the first dose, and at week 4, week 26, and week 52 after the second dose using enzyme-linked immunosorbent assay and flow cytometry, respectively. Reactogenicity, SLE disease activity, including Systemic Lupus Erythematosus Disease Activity Index 2000 and British Isles Lupus Assessment Group-flare rate, were examined. The primary outcome was the proportion of patients with a positive humoral vaccine response 4 weeks after the second dose. The primary and safety analyses were done in a modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT06001606. FINDINGS: Between June 14, and July 19, 2023, 65 patients with SLE were enrolled, of whom 52 were randomly assigned to the herpes zoster subunit vaccine and 13 to placebo. 49 patients in the vaccine group and 11 patients in the placebo group were included in the modified intention-to-treat population. 56 (93%) of 60 patients were women and four (7%) were men. Mean age was 48·7 years (SD 11·4). The proportion of participants with a humoral vaccine response at 4 weeks after the second dose was significantly higher in the vaccine group (48 [98%] of 49 participants) than the placebo group (none [0%] of 11 patients; p<0·0001). More patients in the vaccine group than placebo group reported injection site reactions (42 patients vs two patients), fever (ten vs none), and fatigue (26 vs two). There were no differences in Systemic Lupus Erythematosus Disease Activity Index 2000 and British Isles Lupus Assessment Group-flare rates between the groups. There were no treatment-related deaths. INTERPRETATION: The herpes zoster subunit vaccine induces humoral and cellular immunity against herpes zoster with a good safety profile in patients with SLE. A larger study is warranted to assess the efficacy of vaccines to prevent herpes zoster in patients with SLE. FUNDING: Ministry of Science and ICT, The Government of the Republic of Korea.
引用
- Park JK, Kim M, Jung JI, et al. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024. PMID: 38710192. doi:10.1016/S2665-9913(24)00084-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。